CUREVAC NV (1CVAC.MI) Stock Fundamental Analysis
BIT:1CVAC - NL0015436031 - Common Stock
4.682 EUR
-0.12 (-2.42%)
We assign a fundamental rating of 6 out of 10 to 1CVAC. 1CVAC was compared to 74 industry peers in the Biotechnology industry. 1CVAC is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. 1CVAC is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year 1CVAC was profitable.
1CVAC had a positive operating cash flow in the past year.
1CVAC had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: 1CVAC reported negative operating cash flow in multiple years.
1.2 Ratios
1CVAC has a better Return On Assets (28.11%) than 96.00% of its industry peers.
Looking at the Return On Equity, with a value of 33.02%, 1CVAC belongs to the top of the industry, outperforming 96.00% of the companies in the same industry.
The Return On Invested Capital of 1CVAC (28.35%) is better than 97.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| ROIC | 28.35% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of 1CVAC (37.93%) is better than 92.00% of its industry peers.
1CVAC has a better Operating Margin (40.58%) than 94.67% of its industry peers.
With an excellent Gross Margin value of 94.81%, 1CVAC belongs to the best of the industry, outperforming 90.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 40.58% | ||
| PM (TTM) | 37.93% | ||
| GM | 94.81% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
1CVAC has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for 1CVAC remains at a similar level compared to 1 year ago.
Compared to 5 years ago, 1CVAC has more shares outstanding
The debt/assets ratio for 1CVAC has been reduced compared to a year ago.
2.2 Solvency
1CVAC has an Altman-Z score of 9.65. This indicates that 1CVAC is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of 1CVAC (9.65) is better than 86.67% of its industry peers.
The Debt to FCF ratio of 1CVAC is 0.18, which is an excellent value as it means it would take 1CVAC, only 0.18 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 0.18, 1CVAC belongs to the best of the industry, outperforming 93.33% of the companies in the same industry.
A Debt/Equity ratio of 0.05 indicates that 1CVAC is not too dependend on debt financing.
1CVAC has a Debt to Equity ratio of 0.05. This is in the better half of the industry: 1CVAC outperforms 69.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.18 | ||
| Altman-Z | 9.65 |
ROIC/WACC3.95
WACC7.18%
2.3 Liquidity
1CVAC has a Current Ratio of 6.17. This indicates that 1CVAC is financially healthy and has no problem in meeting its short term obligations.
1CVAC's Current ratio of 6.17 is amongst the best of the industry. 1CVAC outperforms 81.33% of its industry peers.
A Quick Ratio of 6.16 indicates that 1CVAC has no problem at all paying its short term obligations.
1CVAC's Quick ratio of 6.16 is amongst the best of the industry. 1CVAC outperforms 84.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.16 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 170.16% over the past year.
The Revenue has grown by 675.15% in the past year. This is a very strong growth!
1CVAC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 98.42% yearly.
EPS 1Y (TTM)170.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
Revenue 1Y (TTM)675.15%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-91.38%
3.2 Future
The Earnings Per Share is expected to decrease by -22.50% on average over the next years. This is quite bad
Based on estimates for the next years, 1CVAC will show a very negative growth in Revenue. The Revenue will decrease by -11.17% on average per year.
EPS Next Y-165.87%
EPS Next 2Y-62.26%
EPS Next 3Y-31.61%
EPS Next 5Y-22.5%
Revenue Next Year-84.64%
Revenue Next 2Y-56.35%
Revenue Next 3Y-32.7%
Revenue Next 5Y-11.17%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 5.38, the valuation of 1CVAC can be described as very cheap.
Based on the Price/Earnings ratio, 1CVAC is valued cheaply inside the industry as 94.67% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.06, 1CVAC is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for 1CVAC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.38 | ||
| Fwd PE | N/A |
4.2 Price Multiples
1CVAC's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 1CVAC is cheaper than 94.67% of the companies in the same industry.
1CVAC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. 1CVAC is cheaper than 94.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.37 | ||
| EV/EBITDA | 3.07 |
4.3 Compensation for Growth
1CVAC has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as 1CVAC's earnings are expected to decrease with -31.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-62.26%
EPS Next 3Y-31.61%
5. Dividend
5.1 Amount
No dividends for 1CVAC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIT:1CVAC (8/18/2025, 7:00:00 PM)
4.682
-0.12 (-2.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners4.6%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap1.05B
Analysts72.31
Price Target4.22 (-9.87%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-29.18%
Min EPS beat(2)-39.67%
Max EPS beat(2)-18.68%
EPS beat(4)2
Avg EPS beat(4)34.62%
Min EPS beat(4)-39.67%
Max EPS beat(4)161.44%
EPS beat(8)3
Avg EPS beat(8)-1.81%
EPS beat(12)5
Avg EPS beat(12)-8.17%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-91.68%
Min Revenue beat(2)-96.47%
Max Revenue beat(2)-86.88%
Revenue beat(4)2
Avg Revenue beat(4)79.51%
Min Revenue beat(4)-96.47%
Max Revenue beat(4)383.16%
Revenue beat(8)4
Avg Revenue beat(8)55.15%
Revenue beat(12)4
Avg Revenue beat(12)22.54%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.83%
PT rev (3m)-43.91%
EPS NQ rev (1m)-549.77%
EPS NQ rev (3m)87.5%
EPS NY rev (1m)11.05%
EPS NY rev (3m)-14.06%
Revenue NQ rev (1m)-25.01%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)17.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.38 | ||
| Fwd PE | N/A | ||
| P/S | 2.07 | ||
| P/FCF | 5.37 | ||
| P/OCF | 5.17 | ||
| P/B | 1.8 | ||
| P/tB | 1.88 | ||
| EV/EBITDA | 3.07 |
EPS(TTM)0.87
EY18.58%
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)0.87
FCFY18.61%
OCF(TTM)0.91
OCFY19.36%
SpS2.27
BVpS2.6
TBVpS2.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| ROCE | 33.37% | ||
| ROIC | 28.35% | ||
| ROICexc | 78.22% | ||
| ROICexgc | 88.03% | ||
| OM | 40.58% | ||
| PM (TTM) | 37.93% | ||
| GM | 94.81% | ||
| FCFM | 38.42% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.18 | ||
| Debt/EBITDA | 0.14 | ||
| Cap/Depr | 44.58% | ||
| Cap/Sales | 1.55% | ||
| Interest Coverage | 91.31 | ||
| Cash Conversion | 90.71% | ||
| Profit Quality | 101.3% | ||
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.16 | ||
| Altman-Z | 9.65 |
F-Score9
WACC7.18%
ROIC/WACC3.95
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)170.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
EPS Next Y-165.87%
EPS Next 2Y-62.26%
EPS Next 3Y-31.61%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)675.15%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-91.38%
Revenue Next Year-84.64%
Revenue Next 2Y-56.35%
Revenue Next 3Y-32.7%
Revenue Next 5Y-11.17%
EBIT growth 1Y171.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-152.22%
EBIT Next 3Y-32.99%
EBIT Next 5YN/A
FCF growth 1Y160.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y182.06%
OCF growth 3YN/A
OCF growth 5YN/A